Coherus BioSciences, Inc (CHRS): Rasio rega marang pendapatan

The stabilization of Coherus Biosciences (CHRS) image in immuno-oncology on GURU.Markets is reflected in this P/S chart, which captures the metric at 1.60. Coherus Biosciences is implementing an aggressive corporate culture with transparent KPIs for clinicians. However, aggressive dumping and patent disputes in the biosimilars sector create significant risks, necessitating a precise alignment of market value with the business's actual revenue.

CHRS Multiplikator P/S Coherus Biosciences (04.07.2022 - 15.11.2026)

Coherus BioSciences, Inc (CHRS) - rincian metrik lan laporan keuangan

- kuotasi saiki lan rata-rata prakiraan nilai:

Rega bursa Coherus|CHRS - Bagan rega target

- data kapitalisasi bursa:

Nilai pasar Coherus BioSciences|CHRS - Nilai Total Perusahaan

- statistik nilai buku emiten:

Nilai Aset Bersih saben Saham Coherus BioSciences|CHRS - Kapitalisasi Buku|Rasio Nilai Pasar marang Ekuitas coherus.com|CHRS - Gunggung Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

Utang marang Modal Coherus Biosciences|CHRS - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Coherus BioSciences|CHRS - Gunggung utang perusahaan|Utang marang modal buku Coherus BioSciences, Inc|CHRS - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Coherus BioSciences|Likuiditas darurat coherus.com

- data bathi lan kelipatan valuasi:

CHRS - Bathi resik perusahaan|Penghasilan resik sing dikarepake Coherus Biosciences|CHRS - Pangali P/E|Pangali Forward P/E Coherus BioSciences Inc.|CHRS - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi operasional sadurunge panyusutan Coherus BioSciences, Inc.|CHRS - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben siji saham sajrone rolas wulan pungkasan Coherus BioSciences|CHRS - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan coherus.com|CHRS - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Coherus Biosciences

- rincian pendapatan lan dodolan emiten:

CHRS - Pendapatan lan volume dodolan|Pendapatan mangsa ngarep perusahaan Coherus BioSciences, Inc|CHRS - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Coherus BioSciences|CHRS - Wutah dodolan YoY sajrone rolas wulan kepungkur

Ringkesan analitik perusahaan:Coherus BioSciences

Investors are assessing the resilience of Coherus Biosciences (CHRS) through the price-to-sales ratio, which determines the value of every dollar of revenue. By analyzing this price-to-sales chart, one can gauge the market's confidence in the commercial success of LOQTORZI and its biosimilars to avoid the risks of long-term asset impairment under undervalued multiples.

Perusahaan pesaing

INCY - Rega marang dodolan|Rasio rega marang pendapatan hutch-med.com HCM|Nuvation Corp - Rasio rega marang pendapatan|DAWN - Rasio rega marang pendapatan|Rega marang dodolan Monopar Therapeutics|INBX: Multiplikator P/S|Multiplikator rega marang pendapatan I-Mab IMAB|Kapitalisasi marang pendapatan FENC|Rega marang dodolan Heron Therapeutics, Inc. HRTX|Kapitalisasi marang pendapatan NVCT (Nuvectis Pharma, Inc.)|CRBP (Corbus Pharmaceuticals Holdings) - Rasio kapitalisasi pasar marang pendapatan|Cardiff Oncology - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan BYSI (BeyondSpring)|BioAtla - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan LIXT (Lixte Biotechnology Holdings)|CTXR: Multiplikator P/S|Rega marang dodolan cellectar.com (CLRB)|Rasio rega marang pendapatan BioLineRx|CANF: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S APRE|Multiplikator P/S Kazia Therapeutics Ltd (KZIA)|Rasio rega marang pendapatan Silexion Therapeutics Corp. SLXN|NCNA (nucana.com) - Rasio rega marang dodolan|CMRX: Kapitalisasi marang pendapatan|Rega marang dodolan Cyclacel|GTHX: Multiplikator P/S|Kronos Bio Corporation (KRON) - Multiplikator P/S|KTRA (kintara.com) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan ONCT (Oncternal Therapeutics)|Rasio rega marang pendapatan Portage Biotech (PRTG)